Article
Pharmacogenomic heterogeneity of N-acetyltransferase 2: a comprehensive analysis of real world data in Indian tuberculosis patients and from literature and database review.
Annals of medicine - 1 Dec 2025
Thomas Levin, Chaithra, Batra Yashi, Mathur Mitali, Kulavalli Shrivathsa, Sv Chidananda Sanju, Dutt Naveen, Bhardwaj Pankaj, Varma Muralidhar, Saravu Kavitha, Banerjee Mithu, Rao Mahadev
Abstract excerpt
BACKGROUND: Isoniazid is primarily metabolized by the arylamine N-acetyltransferase 2 (NAT2) enzyme. Single nucleotide polymorphisms (SNPs) in the NAT2 gene could classify an individual into three distinct phenotypes: rapid, intermediate and slow acetylators. NAT2 SNPs and the slow acetylator phenotype have been implicated as risk factors for the development of antitubercular drug-induced liver injury (AT-DILI)...
Read the complete abstract on PubMedTopics
- Humans
- Arylamine N-Acetyltransferase
- India
- Polymorphism, Single Nucleotide
- Antitubercular Agents